
GEMS faces scrutiny over costs, governance, and reserves
Parliamentary questions extend from fraud and outsourcing to trustee remuneration and benefit design, while the scheme’s reserves remain below the statutory requirement.

Parliamentary questions extend from fraud and outsourcing to trustee remuneration and benefit design, while the scheme’s reserves remain below the statutory requirement.

Operational improvements have reduced the disruption, but short-paid and unpaid claims, tariff discrepancies, and difficult authorisations continue to require attention.

Executives acknowledged the disruption caused by the June administrator switch while insisting the scheme’s long-term strategy remains on track.

The regulator has clarified the scope of its oversight of Bonitas, confirming that two separate regulatory processes are under way.

Medscheme says the CMS has broadened its investigation into Bonitas’s procurement processes, but Bonitas disputes that interpretation.

The regulator says it is monitoring the situation and sees signs of improvement, but some members continue to report difficulties accessing healthcare and resolving claims.

Medscheme says it repeatedly warned Bonitas against a ‘clean-cut’ transition and disputes the scheme’s claim that unresolved legacy issues were behind the service disruptions experienced by members after the administration switch.

The scheme says continuity of care remains the priority as it moves administration to Momentum Health and managed care to PHA on 1 June.

From broker commissions to digital channels and claims processing, Momentum Health has set out what stakeholders can expect when Bonitas changes administrators.

Private Health Administrators outlines how provider contracts, managed-care operations, and service commitments will work from 1 June.

The appointment strengthens Medscheme’s foothold in the employer-based healthcare sector.

Sanlam and Momentum outline how they are managing workforce, operations, and risk as the Bonitas transition proceeds despite an unresolved court challenge.

Medscheme’s bid to halt Bonitas’ administration transition has been delayed after procedural lapses and unresolved interlocutory issues forced the matter off the urgent roll.

Bonitas, Medscheme, and PHA trade accusations as court papers, whistleblower claims, and a CMS probe intensify the battle over medical scheme contracts.

The scheme and the regulator say a narrowly focused investigation will not halt the transition – but members should brace for some operational changes.

Bonitas’ decision to change administrators comes amid a CMS investigation and High Court proceedings involving its former service provider.

After concluding its section 43 inquiry into Bonitas, the CMS has determined that the allegations merit a further forensic investigation.